Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Sarcoma

4513 - Imatinib in combination with everolimus in patients with progressive advanced chordoma: results form an Italian phase 2 clinical trial.

Date

11 Sep 2017

Session

Sarcoma

Topics

Cytotoxic Therapy;  Sarcoma

Presenters

Silvia Stacchiotti

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

S. Stacchiotti1, C. Morosi2, A. Casale2, E. Palassini1, A.M. Frezza1, A. Messina2, A. Gronchi3, G. Garrone4, E. Venturelli4, S. Pilotti5, E. Tamborini6, P.G. Casali1

Author affiliations

  • 1 Adult Mesenchymal Tumor Medical Oncology Unit, Cancer Medicine Dpt, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Radiology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Department Of Surgery, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 4 Epidemiology And Prevention Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 5 Pathology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 6 Molecular Biology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
More

Resources

Abstract 4513

Background

To evaluate the antitumor activity of imatinib in combination with everolimus in patients (pts) with advanced PDGFB- and/or PDGFRB-positive chordomas with evidence of mTOR and/or of its effectors (i.e. S6, 4EBP1) activation.

Methods

Within an Italian academic prospective phase II clinical study carried out from January 2011 to March 2015, 45 patients with advanced PDGFB/PDGFRB and mTOR/S6/4EBP1 positive chordoma received imatinib 400 mg/day in combination with everolimus at the starting dose of 2.5 mg/day, until progression or limiting toxicity. Eligible pts had to have evidence of progression in the 6 months prior to study entry. The primary endpoint was overall tumor response rate (ORR), defined by the Choi criteria applied also to MRI. Secondary endpoints were RECIST response, progression-free survival (PFS), overall survival (OS).

Results

Fifteen of 45 pts included in the study were pretreated with imatinib (as a single agent). All pts completed their treatment (22 progression; 16 toxicity; 7 other). Among 38/46 patients evaluable by Choi criteria, the best response was: 8 partial response (PR) (ORR, 21%), 23 stable disease (60%) and 7 progression. 42/46 pts were evaluable by RECIST with 1 PR (2%), 36 SD (85%) and 3. Median PFS by Choi criteria was 10 months (range 1-45), with 36% and 17% pts disease-free at 12 and 24 mos, respectively. Median PFS by RECIST was 13 months. At a median follow-up of 31 months, median OS was 47 months.

Conclusions

Although formally negative (the planned target was a Choi ORR ≥60%), this study showed that imatinib + everolimus is active in a proportion of progressive advanced chordoma pts. Major dimensional responses were uncommon but disease stabilization was apparently longer than observed with imatinib as a single agent. Toxicity was not negligible.

Clinical trial identification

EudraCT number: 2010-021755-34

Legal entity responsible for the study

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Funding

AIFA (Agenzia Italiana per il Farmaco)

Disclosure

S. Stacchiotti, E. Palassini, A.M. Frezza: Novartis, research funding to my Institution for clinical trial in which I am involved. A. Gronchi: Novartis: Advisory Board (compensated), Honoraria. P.G. Casali: Novartis, Advisory Board (compensated), Honoraria, Research funding to my Institution for clinical trial in which I am involved. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.